The novel hormone irisin has the ability to drive the cognitive benefits of exercise, and therefore holds great promise for treating cognitive decline in Alzheimer’s disease, scientists at Massachusetts General Hospital (MGH) have found. In a study published in Nature Metabolism, the team reported that irisin, secreted by the muscles during exercise, could be an effective therapeutic for addressing deficits of the brain that result from Alzheimer’s disease.
“Preserving cognitive function is a major challenge in an increasingly aging population,” says Christiane Wrann, DVM, Ph.D., leader of the Program in Neuroprotection in…
